Ask Warren

Enbioco

352940 · KOSDAQ · ₩352940 · 인바이오

₩1,920▲ ₩36 (1.91%)End-of-day · Oct 30, 2026 · End-of-day prices.
Trade
Alert me
SellBuy
AnnualQuarterly

Income statement

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Revenue₩10B₩14B₩7.7B₩3.9B₩8.5B₩14B₩5.2B₩6B
Cost of sales₩5.6B₩8B₩5.3B₩3.2B₩5.9B₩7.8B₩5.1B₩4.1B
Gross profit₩4.9B₩6.1B₩2.4B₩765M₩2.6B₩6.1B₩34M₩1.9B
Operating income₩172M₩3.1B−₩729M−₩1.3B−₩167M₩3.2B−₩2.2B−₩538M
Net income−₩41M₩2.2B−₩482M−₩1.1B₩182M₩2.4B−₩1.8B−₩615M
Net income to shareholders−₩41M₩2.2B−₩482M−₩1.1B₩182M₩2.4B−₩1.8B−₩615M

Balance sheet

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Total assets₩79B₩74B₩69B₩66B₩70B₩75B₩68B₩69B
Current assets₩45B₩42B₩36B₩38B₩43B₩47B₩40B₩44B
Cash and equivalents₩2.5B₩34M₩2.9B₩1.2B₩765M₩587M₩938M₩1.5B
Total liabilities₩34B₩30B₩27B₩24B₩26B₩31B₩26B₩26B
Current liabilities₩26B₩20B₩22B₩18B₩21B₩26B₩22B₩21B
Borrowings₩24B₩18B₩13B₩15B₩15B₩18B₩14B₩16B
Total equity₩45B₩45B₩42B₩43B₩44B₩44B₩41B₩43B
Shareholders' equity₩45B₩45B₩42B₩43B₩44B₩44B₩41B₩43B

Cash flow

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Cash from operations₩2.9B−₩7.8B₩8B₩2B₩3.3B−₩4.2B₩3.2B₩1.6B
Capital spending−₩5.5B−₩7.3M−₩4.1B−₩4.4B₩1B₩563M₩1.6B₩194M
Free cash flow−₩2.6B−₩7.8B₩3.9B−₩2.4B₩2.3B−₩4.7B₩1.6B₩1.4B

Consolidated where available. Amounts in won.

Also known as: Enbioco / 인바이오 / 352940 / KRX:352940

Source: KRX statistical information